Article
Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern.
Nature microbiology - 1 Nov 2021
Dupont Liane, Snell Luke B, Graham Carl, Seow Jeffrey, Merrick Blair, Lechmere Thomas, Maguire Thomas J A, Hallett Sadie R, Pickering Suzanne, Charalampous Themoula, Alcolea-Medina Adela, Huettner Isabella, Jimenez-Guardeño Jose M, Acors Sam, Almeida Nathalia, Cox Daniel, Dickenson Ruth E, Galao Rui Pedro, Kouphou Neophytos, Lista Marie Jose, Ortega-Prieto Ana Maria, Wilson Harry, Winstone Helena, Fairhead Cassandra, Su Jia Zhe, Nebbia Gaia, Batra Rahul, Neil Stuart, Shankar-Hari Manu, Edgeworth Jonathan D, Malim Michael H, Doores Katie J
Abstract excerpt
COVID-19 vaccine design and vaccination rollout need to take into account a detailed understanding of antibody durability and cross-neutralizing potential against SARS-CoV-2 and emerging variants of concern (VOCs). Analyses of convalescent sera provide unique insights into antibody longevity and cross-neutralizing activity induced by variant spike proteins, which are putative vaccine candidates. Using sera from...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.